Sterilization Equipment Market: as Getinge updates its flagship steam sterilizer platform and simultaneously partners with an off-site reprocessing specialist to expand hospital capacity beyond what any single facility can support internally, equipment innovation and outsourced processing capacity are converging on the same underlying pressure, sterile processing departments strained by staffing shortages and rising surgical volume that in-house infrastructure alone can no longer absorb.

The global sterilization equipment market size was USD 11.24 Billion in 2025 and is expected to register a revenue CAGR of 7.5% during the forecast period.Market revenue growth is driven by factors such as expanding low-temperature modality adoption for heat-sensitive polymer and robotic surgical instrumentation, pharmaceutical biologics manufacturing growth driving capital equipment demand, and expanding off-site and outsourced sterile processing capacity addressing hospital staffing constraints.The first driving factor is expanding low-temperature hydrogen peroxide and vaporised hydrogen peroxide sterilization system adoption at academic medical centres and ambulatory surgery centres managing the increasing volume of heat-sensitive polymer and delicate optical instruments introduced by minimally invasive and robotic surgical procedures.The second driving factor is pharmaceutical biologics manufacturing growth, sustaining structural capital equipment demand for sterilization systems supporting drug product and packaging sterility across the expanding biologics production base.The third driving factor is expanding off-site and outsourced sterile processing capacity, as hospitals facing staffing shortages, ageing facilities, and increasing surgical volumes increasingly turn to accredited external reprocessing partners as a scalable alternative to expanding traditional in-house sterile processing departments.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way an equipment manufacturer's partnership with an off-site reprocessing operator widens its addressable hospital customer base every time a hospital facing internal capacity constraints adopts the combined offering, converting a single strategic partnership into recurring equipment and service revenue across every hospital that chooses off-site processing rather than expanding in-house capital investment.Once an equipment manufacturer partners with an accredited off-site sterile processing operator, hospitals facing staffing shortages or ageing facility constraints gain a scalable capacity alternative that does not require in-house capital expansion, so the equipment manufacturer captures both the off-site facility's equipment needs and an expanding pipeline of hospital customers who might otherwise have delayed sterilization equipment investment entirely.As a result, demand and revenue share are concentrating around equipment manufacturers offering combined capital equipment, digital traceability, and off-site processing capacity partnerships, that hold the deepest combined manufacturing and outsourced service capability, and the forecast tilts toward these integrated capacity providers rather than manufacturers offering equipment sales alone.For instance, in December 2025, Getinge announced a strategic partnership with SteriPro International to accelerate the adoption of off-site sterile processing services across the United States, combining Getinge's global leadership in sterilisation equipment, automation, and digital traceability with SteriPro's large-scale, accredited reprocessing operations serving hospitals strained by staffing shortages, ageing facilities, and increasing surgical volumes.These are some of the key factors driving revenue growth of the market.

Because the US Environmental Protection Agency tightened ethylene oxide emission limits in 2024, this has raised operating costs for commercial EtO sterilization chambers and is nudging facilities toward hydrogen peroxide cycles that leave no carcinogenic residuals, requiring capital reinvestment across the installed EtO equipment base.

Cobalt-60 supply disruption is a second constraint, as cobalt-60 shortages are accelerating the pivot toward electron-beam sterilization lines that rely on high-energy electricity rather than isotopes, requiring gamma irradiation operators to plan capacity investment around a less certain long-term radioisotope supply outlook.

Sterile processing department staffing shortages are a third constraint, as hospitals face persistent difficulty recruiting and retaining qualified sterile processing technicians, limiting the pace at which even well-capitalised facilities can expand in-house processing capacity regardless of available equipment investment.

These factors substantially limit sterilization equipment market growth over the forecast period.

The clearest driver of demand is continued manufacturer investment in updating flagship steam sterilization platforms even as low-temperature technology adoption accelerates, reflecting steam's continued position as the largest single sterilization equipment category. A sterile processing department only replaces an existing steam sterilizer platform if the updated system delivers meaningful workflow or capacity improvement, and Getinge's release of the updated Solsus 66 Steam Sterilizer in November 2025 was specifically designed to address evolving central sterile supply department requirements. Steam sterilization remains the anchor technology for the majority of reusable surgical instrument reprocessing, with hydrogen-peroxide plasma, ethylene oxide, and ozone platforms increasingly layered onto existing steam capacity rather than replacing it wholesale. Hospitals and clinics held the majority share of the sterilization equipment market in 2025, while ambulatory surgery centres are growing at a meaningfully faster rate, reflecting the broader shift of surgical procedure volume toward outpatient settings that also require sterilization infrastructure investment. The effect on the market is that steam sterilization technology continues to anchor base capacity even as capital investment increasingly shifts toward layering low-temperature systems on top of, rather than replacing, existing steam infrastructure. These are some of the key factors driving revenue growth of the market.

The second driver is the emergence of off-site, outsourced sterile processing as a genuine capacity alternative to expanding in-house sterile processing department infrastructure, particularly for hospitals facing staffing and facility constraints that equipment investment alone cannot solve. A hospital only adopts off-site sterile processing at scale if the combined equipment and service offering genuinely resolves both the capacity and staffing constraints it faces, and Getinge's partnership with SteriPro International combines Getinge's sterilisation equipment, automation, and digital traceability leadership with SteriPro's large-scale, accredited reprocessing operations and consulting expertise. SteriPro operates one of the largest accredited off-site reprocessing centres in the United States and has spent more than a decade supporting hospitals with workflow design, validation, quality management, compliance, and logistics, providing the operational expertise that complements Getinge's equipment manufacturing strength. The principles used in off-site sterile processing facilities, including controlled airflow, HEPA filtration, validated workflows, and rigorous contamination control, closely align with cleanroom technologies, reflecting the increasing sophistication these outsourced facilities must meet to serve hospital-grade reprocessing needs. The effect on the market is that equipment manufacturers with off-site processing partnerships are capturing hospital customers who might otherwise delay sterilization capacity investment entirely, given persistent sterile processing staffing shortages that in-house expansion alone cannot address. These are some of the key factors driving revenue growth of the market.

“Getinge's partnership with SteriPro International combines global sterilisation equipment and digital traceability leadership with large-scale, accredited off-site reprocessing operations, giving hospitals strained by staffing shortages and rising surgical volumes a scalable capacity alternative that in-house expansion alone cannot provide.”

However, the sterilization equipment market faces severe adoption constraints from ethylene oxide regulatory constraints, cobalt-60 supply disruption, and sterile processing department staffing shortages.

Because the US Environmental Protection Agency tightened ethylene oxide emission limits in 2024, this has raised operating costs for commercial EtO sterilization chambers and is nudging facilities toward hydrogen peroxide cycles that leave no carcinogenic residuals, requiring capital reinvestment across the installed EtO equipment base that not all facilities can immediately absorb.

Cobalt-60 supply disruption compounds this, as shortages are accelerating the pivot toward electron-beam sterilization lines that rely on high-energy electricity rather than isotopes, requiring gamma irradiation operators to plan capacity investment around a less certain long-term radioisotope supply outlook that adds planning complexity beyond routine equipment replacement cycles.

Sterile processing department staffing shortages are the third constraint, as hospitals face persistent difficulty recruiting and retaining qualified sterile processing technicians, limiting the pace at which even well-capitalised facilities can expand in-house processing capacity regardless of available equipment investment, reinforcing the growing appeal of off-site processing alternatives.

These factors substantially limit sterilization equipment market growth over the forecast period.

Based on product type, the global sterilization equipment market is segmented into steam sterilizers, low-temperature sterilizers, radiation sterilization systems, and sterilization containers/accessories. Steam sterilizers hold the largest revenue share, because moist heat sterilization remains the anchor technology for the majority of reusable surgical instrument reprocessing across hospital and ambulatory surgical centre settings globally. Low-temperature sterilizers are expected to register the fastest revenue growth rate over the forecast period, driven by expanding hydrogen peroxide and vaporised hydrogen peroxide adoption for heat-sensitive robotic and flexible endoscope reprocessing.

Based on technology, the global sterilization equipment market is segmented into moist heat, dry heat, low-temperature gas, and radiation sterilization modalities. Moist heat holds the largest technology revenue share, reflecting its established position as the standard reprocessing method for the broadest range of reusable surgical instrumentation. Low-temperature gas is expected to register the fastest revenue growth rate, driven by growing demand for chemical-free, residual-free sterilization cycles compatible with sensitive polymer and electronic surgical instrument components.

Based on regional analysis, the sterilization equipment market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the headquarters of STERIS and the largest concentration of hospital sterile processing infrastructure, and because EPA ethylene oxide regulation directly shapes national technology selection and capital equipment investment decisions. Getinge's SteriPro partnership, specifically targeting US off-site sterile processing capacity expansion, reflects the concentration of both regulatory pressure and staffing constraint challenges at the US national level. The concentration of leading sterilization equipment manufacturers in the United States also means new low-temperature technologies and off-site processing partnership models are often piloted domestically before international market expansion.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national markets, with Getinge anchoring the region's sterilization equipment manufacturing base. European hospital infection prevention guidelines continue to drive sterilization equipment investment, but national procurement and regulatory harmonisation cycles create more measured technology adoption pacing than in the United States. The result is steady rather than rapid growth, shaped more by national procurement cycle timing than by underlying clinical demand.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period, driven by China, Japan, and India's expanding hospital infrastructure and pharmaceutical manufacturing capacity. China's rapidly expanding hospital network and pharmaceutical biologics manufacturing base, and Japan's established sterile processing infrastructure standards, are the region's two largest growth contributors. This leaves more room for growth than in the more mature North American and European sterilization equipment markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with sterilization equipment access concentrated at private hospital networks in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised sterilizer chamber, hydrogen peroxide cartridge, and radiation source components that Latin American sterilization equipment distributors depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed component costs and slowing equipment distribution beyond the region's main hospital networks through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new demand for hospital infection control infrastructure. The UAE is the most established market on the continent for advanced sterilization equipment adoption, while the Gulf states more broadly are still building sterile processing infrastructure largely from scratch.